Press Release Jan 15 2026
Filed with NSE · · 5 pages · English
Further to our intimation dated 26 November 2025, enclosed herewith is a copy of the press release titled “Sun Pharma announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)” which shall be released after this intimation. (Anoop Deshpande) Company Secretary and Compliance Officer Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelim
Sun Pharmaceutical Industries Limited on 6ix
Earlier from Sun Pharmaceutical Industries
- Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
- ILUMYA® (tildrakizumab) Pen (Auto-Injector) Now Available for Canadians Living with Moderate-to-Severe Plaque Psoriasis
- Sun Pharma Launches ILUMYA® In India
- Press Release Dec 01 2025
- Press Release Nov 26 2025
Later from Sun Pharmaceutical Industries
- Sun Pharma Announces the Availability of UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma
- Sun Pharmaceutical Industries Limited Press Release Jan 23 2026
- Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care
- U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
- Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami
Follow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries